Determination of clozapine and its metabolite, norclozapine in various biological matrices using high-performance liquid chromatography

Drug Development and Industrial Pharmacy

Volumn 33, Issue 10, 2007, Pages 1158-1166

  Rosland, Micheal ^a   Szeto, Priscilla ^a   Procyshyn, Ric ^a,b   Barr, Alasdair M ^a   Wasan, Kishor M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b RIVERVIEW HOSPITAL   (Canada)

Author keywords

Clozapine; HPLC; Human plasma; Lipoprotein fractions; Norclozapine; Rat plasma

Indexed keywords

ACETONITRILE; AMMONIUM ACETATE; CHLORIDE; CLOZAPINE; CLOZAPINE N OXIDE; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOXAPINE; METHANOL; NORCLOZAPINE; TERT BUTYL METHYL ETHER; TRIACYLGLYCEROL;

ACCURACY; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DETERMINATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIPOPROTEIN BLOOD LEVEL; LIQUID LIQUID EXTRACTION; NONHUMAN; PH; PLASMA; QUANTITATIVE ANALYSIS; RAT; STANDARD;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLOZAPINE; HUMANS; QUALITY CONTROL; RATS;

EID: 35648929449     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040701484338     Document Type: Article

References (12)

1. Almeida, A. M., Castel-Branco, M. M. et al. (2002). Linear regression for calibration lines revisited: Weighting schemes for bioanalytical methods. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 774(2), 215-222.
2. Ananth, J., Parameswaran, S., & Hara, B. (2004). Drug therapy in schizophrenia. Curr. Pharm. Des., 10(18), 2205-2217.
3. Byerly, M. J., & DeVane, C. L. (1996). Pharmacokinetics of clozapine and resperidone: A review of recent literature. J. Clin. Psychopharmacol., 16(2), 177-187.
4. Honer, W. G., Thornton, A. E., Chen, E. Y. H., Chan, R. C. K., Wong, J. O. Y., Bergmann, A., Falkai, P., Pomarol-Clotet, E., McKenna, P. J., Stip, E., Williams, R., MacEwen, G. W., Wasan, K. M., Procyshyn, R. (2006). Clozapine alone versus clozapine and resperidone with refractory schizophrenia. N. Eng. l J. Med., 354(5), 472-482.
5. Horacek, J., Bubenikova-Valesova, V., Kopecek, M., Palenicek, T., Dockery, C., Mohr, P., & Hoschi, C. (2006). Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs, 20(5), 389-409.
6. Khan, A. Y., & Preskorn, S. H. (2005). Examining concentration- dependant toxicity of clozapine: Role of therapeutic drug monitoring. J. Psychiatr. Pract., 11(5), 289-301.
7. Kuppamaki, M., Syvalahti, E., & Hietala, J. (1993). Clozapine and N-desmethylclozapine are potent 5-HT1C receptor antagonists. Eur. J. Pharmcol., 245(2), 179-182.
8. Procyshyn, R. M., Ho, T., Wasan, K. M. (2005). Competitive displacement of clozapine from plasma proteins in normolipidimic and hyperlipidimic plasma samples: Clinical implications. Drug Dev. Ind. Pharm., 31(4-5), 331-337.
9. Procyshyn, R. M., Kennedy, N. B., Marriage, S., & Wasan, K. M. (2001). Plasma protein and lipoprotein distribution of clozapine. Am. J. Psychiatry., 158(6), 949-951.
10. Ma, F., & Lau, C. E. (1998). Determination of clozapine and its metabolite, N-desmethylclozapine, in serum microsamples by high-performance liquid chromatography and its application to pharmacokinetics in rats. J. Chromatogr. B Biomed. Sci. Appl., 712(1-2), 193-198.
11. Mosier, K. E., Song, J., McKay, G., Hubbard, J. W., Fang, J. (2003). Determination of clozapine, and it metabolites, N-desmethylclozapine and clozapine N-oxide in dog plasma using high-performance liquid chromatography. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 783(2), 377-382.
12. Wasan, K. M., Cassidy, S. M., Ramaswamy, M., Kennedy, A., Strobel, F. W., Ng, S. P., & Lee, T. Y. (1999). A comparison of step-gradient and sequential density ultracentrifugation and the use of lipoprotein deficient plasma controls in determining the plasma lipoprotein distribution of lipid associated nystatin and cyclosporine. Pharm. Res., 16(1), 165-169.